Archer® VariantPlex®: The new standard in NGS-based myeloid mutation detection

Learn more about
VariantPlex Myeloid assays

Watch the webinar


Webinar abstract

Archer® VariantPlex®: The new standard in NGS-based myeloid mutation detection

Myeloid malignancies are clonally heterogeneous diseases with highly variable mutation landscapes that involve complex chromosomal translocations, insertions and deletions (indels) and single nucleotide variants (SNVs). Traditional molecular assays rely upon multiple platforms to identify mutations but generally lack the ability to thoroughly characterize internal tandem duplications (ITDs), detect variants in difficult regions like CEBPA, and quantitate low allele-frequency variants.

Archer® VariantPlex® myeloid assays combine targeted library preparation with powerful bioinformatics to enable comprehensive variant detection by next-generation sequencing (NGS). VariantPlex assays employ Anchored MultiPlex PCR (AMP™) enrichment chemistry that is purpose-built for targeted enrichment from low-input DNA. Together with updates to the Archer Analysis bioinformatics platform, VariantPlex myeloid assays now deliver unprecedented confidence in mutation detection.

In this webinar, Massachusetts General Hospital pathologist Long Phi Le, MD, PhD, will discuss how updates to the assay and software provide better coverage, lower limits of detection, high-resolution CNV detection and lightning-fast analysis. Brent Lutz, Software Product Manager at ArcherDX, will introduce Dr. Le, as well as review the latest improvements in Archer Analysis.

Topics this webinar will cover:

  • New VariantPlex Myeloid panel features
  • High-confidence variant calling for DNA and ctDNA assays via noise and outlier detection
  • Re-vamped CNV pipeline with exon-level gain/loss detection
  • Powerful new databasing features for analysis and reporting

About the presenters

Long Phi Le, MD, PhD

Long Le

Dr. Le is a molecular pathologist and bioinformaticist with expertise in tumor genotyping for personalized targeted therapies at the Center for Integrated Diagnostics at Massachusetts General Hospital. After earning his MD, PhD from the University of Alabama School of Medicine, Dr. Le completed a residency at Massachusetts General Hospital and a fellowship at Brigham and Women’s Hospital. Dr. Le holds dual appointments as an Assistant in Pathology at Massachusetts General Hospital and an Assistant Professor of Pathology at Harvard Medical School. Dr. Le is one of the co-developers of Anchored Multiplex PCR enrichment chemistry and a co-founder of ArcherDX.

Brent Lutz, MS

Brent Lutz

Brent Lutz is the Product Manager of Software at ArcherDX. He is trained as a biomedical engineer and has 14 years experience commercializing cutting-edge technology for a broad range of life science applications in diagnostic assay and automation development. Outside of his Archer life, Brent is your typical Colorado outdoors enthusiast and has so far climbed 14 of the 53 mountain peaks in Colorado that extend above 14,000 feet in elevation.

How to contact us


2477 55th Street, Suite 202

Boulder, CO 80301


Phone: (877) 771 1093

Phone: (303) 357 9001

All content © 2019 ArcherDX, Inc.

For Research Use Only. Not for use in diagnostic procedures. For Research Use Only. Not for use in diagnostic procedures.